SCHEMBL7215608

SCHEMBL7215608

CC(CC(O)(CS(=O)(=O)c1cc(Cl)ccc1-c1ccccc1)C(=O)NO)Sc1ccccn1

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.37
SHMT1 P34896 4/20 0.35
SHMT2 P34897 2/20 0.35
SMN1; SMN2 Q16637 4/20 0.35
HPGD P15428 1/20 0.35
HSD17B10 Q99714 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.34
TDP1 Q9NUW8 2/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
MEN1 O00255 1/20 0.33
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33
BLM P54132 1/20 0.33
KMT2A Q03164 1/20 0.33
CTDSP1 Q9GZU7 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7212130 0.79 SHMT1 (0.38) ALDH1A1SHMT1SHMT2SMN1; SMN2HPGD
SCHEMBL7215461 0.78 ALDH1A1 (0.44) ALDH1A1SHMT1SHMT2SMN1; SMN2HPGD
SCHEMBL7210908 0.78 MMP2 (0.38) SHMT1PTGDR2TDP1
SCHEMBL7212128 0.77 SHMT1 (0.36) SHMT1SHMT2PTGDR2BLMLMNA
SCHEMBL7215507 0.76 PTGDR2 (0.34) SHMT1PTGDR2
SCHEMBL7215592 0.75 ALDH1A1 (0.39) ALDH1A1SHMT1PTGDR2TDP1RAB9A
SCHEMBL7212142 0.73 MMP1 (0.44) SMN1; SMN2HPGDHSD17B10
SCHEMBL7210467 0.73 SHMT1 (0.38) SHMT1SHMT2PTGDR2MEN1KMT2A
SCHEMBL7210804 0.72 MMP2 (0.38) SHMT1SHMT2PTGDR2
SCHEMBL7210521 0.72 SHMT1 (0.35) SHMT1SHMT2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030166687-A1 ALPHA-HYDROXY,-AMINO AND -FLUORO DERIVATIVES OF BETA-SULPHONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS PHARMACIA & UPJOHN COMPANY 2003-09-04 US claimed
EP-1037868-B1 $g(a)-HYDROXY, -AMINO, AND HALO DERIVATIVES OF $g(b)-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS UPJOHN CO (US) 2003-02-05 EP claimed
US-20030166687-A1 ALPHA-HYDROXY,-AMINO AND -FLUORO DERIVATIVES OF BETA-SULPHONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS PHARMACIA & UPJOHN COMPANY 2003-09-04 US disclosed
EP-1037868-B1 $g(a)-HYDROXY, -AMINO, AND HALO DERIVATIVES OF $g(b)-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS UPJOHN CO (US) 2003-02-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166687-A1 ALPHA-HYDROXY,-AMINO AND -FLUORO DERIVATIVES OF BETA-SULPHONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS MMP1, MMP8, HRH3 ALDH1A1 3218/4885SHMT1 470/4885SHMT2 1906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.